



US006703396B1

(12) **United States Patent**
Liotta et al.

(10) **Patent No.:** US 6,703,396 B1
(b4) **Date of Patent:** Mar. 9, 2004

- (54) **METHOD OF RESOLUTION AND ANTIVIRAL ACTIVITY OF 1,3-OXATHIOLANE NUCLEOSIDE ENANTIOMERS**
- (75) Inventors: **Dennis C. Liotta**, Stone Mountain, GA (US); **Raymond F. Schinazi**, Decatur, GA (US); **Woo-Baeg Choi**, North Brunswick, NJ (US)
- (73) Assignee: **Emory University**, Atlanta, GA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 641 days.
- (21) Appl. No.: **08/402,730**
- (22) Filed: **Mar. 13, 1995**

EP	0337713	4/1989
EP	0 361 831	4/1990
EP	0375329	6/1990
EP	0433898	6/1991
EP	0515157	5/1992
EP	0494119	7/1992
EP	494119	7/1992
EP	0515144	11/1992
EP	0515156	11/1992
EP	0526253	2/1993
WO	WO 88/07532	10/1988
WO	WO 90/12023	10/1990
WO	WO 91/11186	8/1991
WO	WO 91/17159	11/1991
WO	WO 92/08717	5/1992
WO	WO 92/10496	6/1992
WO	WO 92/10497	6/1992
WO	WO 92/14743	9/1992
WO	WO 92/15308	9/1992
WO	WO 92/18517	10/1992
WO	WO 94/04154	3/1994

Related U.S. Application Data

- (63) Continuation of application No. 08/092,248, filed on Jul. 15, 1993, now abandoned, which is a continuation of application No. 07/736,089, filed on Jul. 26, 1991, now abandoned, which is a continuation-in-part of application No. 07/659,760, filed on Feb. 22, 1991, now Pat. No. 5,210,085, which is a continuation-in-part of application No. 07/473,318, filed on Feb. 1, 1990, now Pat. No. 5,204,466.

(30) **Foreign Application Priority Data**

Mar. 6, 1991 (GB)	9104741
May 2, 1991 (GB)	9109505

(51) **Int. Cl. 7** **A61K 31/505**

(52) **U.S. Cl.** **514/274; 514/86; 544/243;**

544/317

(58) **Field of Search** 544/243, 317;
514/274, 86

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,000,137 A	12/1976	Dvonoch et al.	544/313
4,336,381 A	6/1982	Nagata et al.	544/313
4,861,759 A	8/1989	Mitsuya et al.	514/46
4,879,277 A	11/1989	Mitsuya et al.	514/49
4,900,828 A	2/1990	Belica et al.	544/317
4,916,122 A	4/1990	Chu et al.	514/50
4,963,533 A	10/1990	de Clerq et al.	514/49
5,041,449 A	8/1991	Belleau et al.	514/274
5,047,407 A	9/1991	Belleau et al.	544/317
5,059,690 A	10/1991	Zahler et al.	544/276
5,071,983 A	12/1991	Koszalka et al.	544/317
5,179,104 A	1/1993	Chu et al.	544/310
5,185,437 A	2/1993	Koszalka et al.	544/317
5,204,466 A *	4/1993	Liotta et al.	544/317
5,210,085 A *	5/1993	Liotta et al.	544/317
5,234,913 A	8/1993	Furman, Jr. et al.	514/49
5,248,776 A	9/1993	Chu et al.	544/310
5,270,315 A	12/1993	Belleau et al.	544/265
5,538,975 A	7/1996	Dionne	
5,618,820 A	4/1997	Dionne	
5,814,639 A	9/1998	Liotta et al.	

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS

Daniels, T.C. et al. *Textbook of Organic Medicinal and Pharmaceutical Chemistry*, ed. by Wilson, C.O. et al. (Lippincott Co., Philadelphia), pp. 31–36 (1977).*

Carter, S.O. et al. *Antimicrob. Agents Chemotherapy*, vol. 34, pp. 1297–1300 (1990).*

March, J. *Advanced Organic Chemistry* (Wiley and Sons, New York), pp. 82–107 (1985).*

Belleau, B., et al., “Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1,” *International Conference on AIDS*, Montreal, Quebec, Canada Jun. 4–9, 1989.

Krenitsky, T.A., et al., “3'-Amino-2',3'-Dideoxyribonucleosides of Some Pyrimidines: Synthesis and Biological Activities,” *J. Med. Chem.*, Vo. 26 (1993).

Sterzycki, R.Z., et al., “Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides,” *J. Med. Chem.* 33:2150–2157 (1990).

Storer, B., et al., “The Resolution and Absolute Stereochemistry of the Enantiomeris of cis-1-[2-(Hydromethyl)-1,3-Oxathiolan-5-yl]cytosine (BCH189): Equipotent Anti-HIV Agents,” *Nucleosides & Nucleotides*, 12(2) 225–236 (1993).

(List continued on next page.)

Primary Examiner—James O. Wilson

(74) **Attorney, Agent, or Firm—Sherry M. Klowles, Esq.; King & Spalding**

(57) **ABSTRACT**

A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.